{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:59:47Z","timestamp":1791190787613,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantationreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.trre.2015.02.005","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T02:11:53Z","timestamp":1425089513000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Immunosuppressive therapies after heart transplantation \u2014 The balance between under- and over-immunosuppression"],"prefix":"10.1016","volume":"29","author":[{"given":"Carl","family":"S\u00f6derlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"R\u00e5degran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2015.02.005_bb0005","first-page":"1271","article-title":"The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town","volume":"41","author":"Barnard","year":"1967","journal-title":"S Afr Med J"},{"key":"10.1016\/j.trre.2015.02.005_bb0010","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.healun.2012.08.002","article-title":"International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report 2012","volume":"31","author":"Stehlik","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0015","series-title":"Immunobiology","author":"Murphy","year":"2008"},{"key":"10.1016\/j.trre.2015.02.005_bb0020","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1084\/jem.177.6.1643","article-title":"Contribution of direct and indirect recognition pathways to T cell alloreactivity","volume":"177","author":"Liu","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0025","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1073\/pnas.90.14.6586","article-title":"Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation","volume":"90","author":"Gimmi","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trre.2015.02.005_bb0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"International Society of Heart and Lung Transplantation guidelines. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.healun.2006.10.003","article-title":"Cardiac Transplant Research Database Group. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis","volume":"25","author":"Stehlik","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/TP.0b013e318244f7b8","article-title":"Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody","volume":"93","author":"Hodges","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.5858\/2007-131-1169-UOCTP","article-title":"Update on cardiac transplantation pathology","volume":"131","author":"Tan","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1536\/ihj.3.537","article-title":"Endomyocardial biopsy","volume":"3","author":"Sakakibara","year":"1962","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.trre.2015.02.005_bb0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0003-4975(10)65002-3","article-title":"Percutaneous transvenous endomyocardial biopsy in human heart recipients. Experience with a new technique","volume":"16","author":"Caves","year":"1973","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.trre.2015.02.005_bb0065","first-page":"587","article-title":"A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation","volume":"9","author":"Billingham","year":"1990","journal-title":"J Heart Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0070","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.healun.2013.08.011","article-title":"The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation","volume":"32","author":"Berry","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.healun.2010.05.017","article-title":"International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy\u20142010","volume":"29","author":"Mehra","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0085","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/tri.12284","article-title":"Acute cellular rejection the first year after heart transplantation and its impact on survival: a single-centre retrospective study at Sk\u00e5ne University Hospital in Lund 1988\u20132010","volume":"27","author":"S\u00f6derlund","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2015.02.005_bb0090","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2007-0251","article-title":"Malignancy after solid organ transplantation: an overview","volume":"13","author":"Zafar","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.trre.2015.02.005_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.ackd.2005.10.007","article-title":"Chronic kidney disease in solid-organ transplantation","volume":"13","author":"Miller","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.trre.2015.02.005_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1399-0012.2007.00748.x","article-title":"Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study","volume":"22","author":"Yamani","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.TP.0000130179.18176.3D","article-title":"Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction","volume":"78","author":"Cantarovich","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2004.08.003","article-title":"Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation","volume":"24","author":"Rosenberg","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0120","first-page":"CD008842","article-title":"Immunosuppressive T-cell antibody induction for heart transplant recipients","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2015.02.005_bb0125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MOT.0b013e32834a8c61","article-title":"Is induction therapy still needed in heart transplantation?","volume":"16","author":"Aliabadi","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0130","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/tri.12107","article-title":"Induction therapy in heart transplantation: where are we now?","volume":"26","author":"Aliabadi","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2015.02.005_bb0555","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.trre.2015.02.005_bb0560","author":"European Medicines Agency"},{"key":"10.1016\/j.trre.2015.02.005_bb0165","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1053-2498(99)00100-X","article-title":"A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation","volume":"18","author":"Carrier","year":"1999","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0170","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.healun.2011.01.716","article-title":"UK Cardiothoracic Transplant Audit. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study","volume":"30","author":"Emin","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0175","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJM200003023420902","article-title":"Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody","volume":"342","author":"Beniaminovitz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0180","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa032953","article-title":"Daclizumab to prevent rejection after cardiac transplantation","volume":"352","author":"Hershberger","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0185","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healun.2004.09.010","article-title":"A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation","volume":"24","author":"Mehra","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.healun.2007.01.006","article-title":"Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial","volume":"26","author":"Carrier","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0195","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.healun.2007.05.002","article-title":"Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy","volume":"26","author":"Mattei","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0200","first-page":"1","article-title":"A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation","volume":"30","author":"Mullen","year":"2014","journal-title":"Transplant Res"},{"key":"10.1016\/j.trre.2015.02.005_bb0205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.healun.2003.12.014","article-title":"Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection","volume":"24","author":"Carlsen","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.healun.2006.09.002","article-title":"Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation","volume":"25","author":"Flaman","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0215","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.transproceed.2008.07.113","article-title":"Induction immunosuppression with basiliximab in heart transplantation","volume":"40","author":"Chou","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1510\/icvts.2004.105262","article-title":"Induction immunosuppression after heart transplantation: monoclonal vs. polyclonal antithymoglobulins. Is there a difference?","volume":"4","author":"Haddad","year":"2005","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.trre.2015.02.005_bb0225","first-page":"216","article-title":"Campath-1H in clinical heart transplantation","volume":"25","author":"Pham","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0230","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.healun.2009.11.143","article-title":"A randomized study using humanized monoclonal antibody against Cd52 (Campath-1h) and tacrolimus in heart transplant recipients","volume":"29","author":"Pham","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0235","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1600-6143.2009.02856.x","article-title":"Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes","volume":"10","author":"Teuteberg","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.healun.2009.11.317","article-title":"Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: two year outcomes","volume":"29","author":"Shullo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.healun.2011.01.211","article-title":"Steroid-free immunosuppression after routine alemtuzumab induction in cardiac transplantation: three year outcomes","volume":"30","author":"Teuteberg","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.healun.2012.01.201","article-title":"Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: four year outcomes","volume":"31","author":"Teuteberg","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.healun.2013.01.491","article-title":"Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: five year outcomes","volume":"32","author":"Teuteberg","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0260","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7182\/pit2012241","article-title":"Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients","volume":"22","author":"Cahoon","year":"2012","journal-title":"Prog Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0265","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2015.02.005_bb0270","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00228-010-0902-6","article-title":"Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials","volume":"66","author":"Penninga","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.trre.2015.02.005_bb0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1517\/17425255.2012.726219","article-title":"Proliferation signal inhibitor toxicities after thoracic transplantation","volume":"9","author":"Ensor","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.trre.2015.02.005_bb0280","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ehj.2004.06.032","article-title":"Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients\u2014the IMPROVED multi-centre study","volume":"25","author":"Angermann","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.trre.2015.02.005_bb0285","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.tp.0000253883.52525.7c","article-title":"Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients","volume":"83","author":"Hamour","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0290","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0295","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2years: a randomized clinical trial","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2015.02.005_bb0300","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2004-820880","article-title":"First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation","volume":"52","author":"Tr\u00f6sch","year":"2004","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1016\/j.trre.2015.02.005_bb0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2006.02.001","article-title":"Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients","volume":"16","author":"Schweiger","year":"2006","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2015.02.005_bb0310","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.healun.2007.11.565","article-title":"Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients","volume":"27","author":"Ross","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0315","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0320","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":"Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-2277.2009.00940.x","article-title":"Reduction of cyclosporine following the introduction of everolimus in maintenance heart transplant recipients: a pilot study","volume":"23","author":"Ross","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2015.02.005_bb0330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TP.0b013e3181c42b95","article-title":"Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study","volume":"89","author":"Potena","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0335","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.transproceed.2010.12.055","article-title":"Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study","volume":"43","author":"Fuchs","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0340","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1399-0012.2011.01407.x","article-title":"Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients","volume":"26","author":"Khandhar","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0345","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.healun.2012.01.002","article-title":"Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study","volume":"31","author":"Potena","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0350","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.trim.2014.06.002","article-title":"Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus","volume":"31","author":"Fuchs","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2015.02.005_bb0470","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2006.01.004","article-title":"Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients","volume":"25","author":"Balfour","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0475","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1399-0012.2006.00632.x","article-title":"Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients","volume":"21","author":"Potter","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0480","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.healun.2007.07.034","article-title":"Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction","volume":"26","author":"Gustafsson","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0485","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/TP.0b013e3181963371","article-title":"Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure","volume":"87","author":"Groetzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0490","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1399-0012.2009.00963.x","article-title":"Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients","volume":"23","author":"Demirjian","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0495","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1016\/j.transproceed.2009.06.236","article-title":"Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the Spanish Multicenter Observational Study (RAPACOR)","volume":"41","author":"Delgado","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0500","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2013.11.036","article-title":"Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?","volume":"171","author":"Gonzalez-Vilchez","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.trre.2015.02.005_bb0355","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1053-2498(01)00421-1","article-title":"Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment","volume":"21","author":"Snell","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0360","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0041-1345(03)00772-3","article-title":"Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation","volume":"35","author":"Zakliczynski","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0365","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.TP.0000103740.98095.14","article-title":"Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure","volume":"77","author":"Groetzner","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejcts.2003.11.030","article-title":"Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients","volume":"25","author":"Groetzner","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.trre.2015.02.005_bb0375","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2004.10.062","article-title":"Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation","volume":"36","author":"Lyster","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0380","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.healun.2005.02.018","article-title":"Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation","volume":"24","author":"Hunt","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0385","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.transproceed.2005.09.152","article-title":"Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center","volume":"37","author":"Fernandez-Valls","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0390","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.transproceed.2005.02.090","article-title":"Preservation of renal function after heart transplantation: initial single-center experience with sirolimus","volume":"37","author":"De Meester","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0395","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.transproceed.2005.02.006","article-title":"Sirolimus improves renal function in cardiac transplantation","volume":"37","author":"Cabez\u00f3n","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0400","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.healun.2005.08.015","article-title":"Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity","volume":"24","author":"Kushwaha","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0405","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/01.tp.0000177644.45192.a3","article-title":"Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up","volume":"81","author":"Bestetti","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0410","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.transproceed.2006.08.075","article-title":"Sirolimus experience in heart transplantation","volume":"38","author":"Aranda-Dios","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0415","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/j.1600-6143.2006.01527.x","article-title":"Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy","volume":"6","author":"Gleissner","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0420","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.transproceed.2007.06.066","article-title":"mTOR inhibitors: do they help preserve renal function?","volume":"39","author":"Moro","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0425","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.healun.2007.01.017","article-title":"Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6months' follow-up","volume":"26","author":"Rothenburger","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0430","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/01.tp.0000276959.56959.69","article-title":"Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients","volume":"84","author":"Raichlin","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0435","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/TP.0b013e31819452ce","article-title":"Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime","volume":"87","author":"Moro L\u00f3pez","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0440","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.healun.2010.01.005","article-title":"Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation","volume":"29","author":"Gude","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0445","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/TP.0b013e31821774bd","article-title":"Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2years","volume":"91","author":"Engelen","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0450","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.transproceed.2010.12.062","article-title":"Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2years' follow-up from the University Hospital M\u00fcnster","volume":"43","author":"Stypmann","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2015.02.005_bb0455","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0460","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.healun.2010.11.005","article-title":"Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients","volume":"30","author":"Gonz\u00e1lez-Vilchez","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0465","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/j.1600-6143.2012.04131.x","article-title":"Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency","volume":"12","author":"Zuckermann","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0505","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/tri.12309","article-title":"Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature","volume":"27","author":"Baraldo","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2015.02.005_bb0510","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/ctr.12277","article-title":"Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review","volume":"27","author":"Ravichandran","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0515","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0520","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.healun.2005.02.009","article-title":"Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients","volume":"24","author":"Kobashigawa","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2015.02.005_bb0525","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1161\/01.CIR.96.5.1398","article-title":"Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial","volume":"96","author":"Wenke","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2015.02.005_bb0530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2015.02.005_bb0535","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199301213280303","article-title":"A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients","volume":"328","author":"Schroeder","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2015.02.005_bb0540","first-page":"710","article-title":"Calcium blockers and atherosclerosis: lessons from the Stanford Transplant Coronary Artery Disease\/Diltiazem Trial","volume":"11","author":"Schroeder","year":"1995","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.trre.2015.02.005_bb0545","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/TP.0b013e318277e378","article-title":"Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation","volume":"95","author":"Guethoff","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2015.02.005_bb0550","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X15000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X15000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:09:35Z","timestamp":1717769375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X15000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0955470X15000099"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2015.02.005","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive therapies after heart transplantation \u2014 The balance between under- and over-immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2015.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}